Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses.
An adequate effector response against pathogens and its subsequent inactivation after pathogen clearance are critical for the maintenance of immune homeostasis. This process involves an initial phase of T-cell effector (Teff) activation followed by the expansion of regulatory T cells (Tregs), a unique cell population that limits Teff functions. However, significant questions remain unanswered about the mechanisms that regulate the balance between these cell populations. Using an in vitro system to mimic T-cell activation in human peripheral blood mononuclear cells (PBMC), we analysed the patterns of Treg and Teff activation, with special attention to the role of type I interferon (IFN-I). Interestingly, we found that IFN-alpha, either exogenously added or endogenously induced, suppressed the generation of CD4(+) FoxP3(HI )IFN-gamma(Neg) activated Tregs (aTregs) while simultaneously promoting propagation of CD4(+) FoxP3(Low/Neg )IFN-gamma(Pos) activated Teffs (aTeffs). We also showed that IFN-alpha-mediated inhibition of interleukin (IL)-2 production may play an essential role in IFN-alpha-induced suppression of aTregs. In order to test our findings in a disease state with chronically elevated IFN-alpha, we investigated systemic lupus erythematosus (SLE). Plasma from patients with SLE was found to contain IFN-I activity that suppressed aTreg generation. Furthermore, anti-CD3 activated SLE PBMCs exhibited preferential expansion of aTeffs with a very limited increase in aTreg numbers. Together, these observations support a model whereby a transient production of IFN-alpha (such as is seen in an early antiviral response) may promote CD4 effector functions by delaying aTreg generation, but a chronic elevation of IFN-alpha may tip the aTeff:aTreg balance towards aTeffs and autoimmunity.
Golding
Amit
A
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
Rosen
Antony
A
Petri
Michelle
M
Akhter
Ehtisham
E
Andrade
Felipe
F
D000998:Antiviral Agents / Q000276:immunology; D015551:Autoimmunity; D051858:Forkhead Transcription Factors / Q000378:metabolism; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000276:immunology / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology / Q000378:metabolism
D000998:Antiviral Agents; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D016898:Interferon-alpha
Immunol Rev. 2006 Aug;212:8-27
16903903
J Immunol. 1984 Oct;133(4):1710-5
6206131
Annu Rev Immunol. 2009;27:551-89
19302048
Immunol Rev. 2006 Aug;212:149-62
16903912
Immunol Rev. 2005 Feb;203:156-64
15661028
Immunology. 2009 Jun;127(2):196-205
18800986
J Immunol. 2005 Apr 1;174(7):4407-14
15778406
Science. 2003 Feb 14;299(5609):1057-61
12522256
J Immunol. 2005 Jan 15;174(2):767-76
15634897
Annu Rev Immunol. 2008;26:453-79
18062768
J Virol. 2008 Sep;82(17):8307-15
18579608
J Immunol. 2006 Sep 1;177(5):3235-41
16920963
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
12604793
J Immunol. 2005 Dec 15;175(12):8392-400
16339581
J Autoimmun. 2009 Feb;32(1):14-23
19022624
J Gen Virol. 2008 Jan;89(Pt 1):1-47
18089727
Curr Top Microbiol Immunol. 2007;316:337-57
17969455
PLoS One. 2008 Feb 13;3(2):e1581
18324310
Nat Immunol. 2005 Nov;6(11):1152-9
16227983
Science. 2003 Feb 14;299(5609):1033-6
12532024
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64
16617117
J Am Soc Nephrol. 2009 May;20(5):1032-40
19357252
J Clin Immunol. 2008 Nov;28(6):635-9
18726679
Pediatr Infect Dis J. 1996 Oct;15(10):883-6
8895920
Nat Rev Immunol. 2006 Nov;6(11):823-35
17063184
Nat Immunol. 2008 Mar;9(3):239-44
18285775
Immunity. 2006 Sep;25(3):383-92
16979570
J Immunol. 2008 Nov 15;181(10):7356-66
18981159
PLoS One. 2009;4(3):e4948
19319188
J Immunol. 2003 Oct 15;171(8):4352-8
14530360
Eur J Immunol. 2007 Jan;37(1):21-3
17183612
J Immunol. 2007 Jul 1;179(1):154-61
17579033
Nat Clin Pract Rheumatol. 2007 Nov;3(11):619-26
17968332
Curr Opin Rheumatol. 2007 Jan;19(1):61-6
17143098
J Immunol. 2004 Dec 15;173(12):7249-58
15585847
J Clin Invest. 1982 Jun;69(6):1388-92
6979554
J Virol. 2008 Feb;82(4):1870-83
18077723
Nature. 2007 Feb 15;445(7129):766-70
17220876
Science. 2001 Nov 16;294(5546):1540-3
11711679
Blood. 2006 Jul 1;108(1):253-61
16537805
J Immunol. 2000 Mar 1;164(5):2296-302
10679063
J Immunol. 2006 Jun 15;176(12):7278-87
16751371
Immunol Rev. 2006 Apr;210:120-37
16623768
Nat Rev Immunol. 2006 Apr;6(4):295-307
16557261
J Immunol. 2008 Jul 1;181(1):225-34
18566388
Science. 2005 Aug 26;309(5739):1380-4
16123302
J Immunol. 2005 Oct 1;175(7):4635-40
16177109
J Pediatr Gastroenterol Nutr. 1993 Jan;16(1):29-32
8433236
Eur J Immunol. 2006 Oct;36(10):2658-70
16981182
J Leukoc Biol. 2008 Oct;84(4):973-80
18653463
J Exp Med. 2003 Mar 17;197(6):711-23
12642603
Immunity. 2009 Jun 19;30(6):899-911
19464196